Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc.

CGTX

0.00
  • Cognition Therapeutics posted a new press release announcing CEO Lisa Ricciardi will join a fireside chat at B. Riley’s Mind, Muscle & Vision Summit.
  • The July 16, 2026 session will cover the ongoing Phase 2 START study, plans to launch a Phase 3 registrational trial of zervimesine (CT1812) in DLB psychosis.
  • A replay is expected to be available on the company’s investor relations site at https://cogrx.com.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130730PRIMZONEFULLFEED9760503) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.